Cardiogen 20mg
Synthetic short-chain tetrapeptide bioregulator studied for its potential effects on cardiomyocyte gene expression and cardiovascular integrity.
Mechanism
Hypothesized to penetrate nuclear boundaries and bind promoter regions of genomic DNA to modulate tissue-specific gene expression supporting cardiomyocyte survival.
Dosing
Standard laboratory protocols initiate research with a baseline dose of 200 mcg administered once daily.
Reconstitution
Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water produces a final working concentration of approximately 6.67 mg/mL.
Storage
Keep the lyophilized vial frozen at -20 °C in darkness, and refrigerate the reconstituted solution between 2 °C and 8 °C for up to 28 days without freezing.
Mix & measure Cardiogen 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Cardiogen 20mg
Vial strength → BAC water → target dose
Total doses in vial: 100.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (1× daily) | ~3 units (0.03 mL) |
| Weeks 3–4 | 300 mcg (1× daily) | ~4.5 units (0.045 mL) |
| Week 5 | 400 mcg (1× daily) | ~6 units (0.06 mL) |
| Weeks 6–12 | 500 mcg (1× daily) | ~7.5 units (0.075 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release the diluent slowly down the interior glass wall of the vial to prevent foaming.
- 3
Swirl or rotate the vial gently until the cake is completely dissolved, taking care not to shake.
- 4
Record the date and concentration on the vial label, then place in refrigerated storage at 2–8 °C protected from light.
Supplies Needed
Peptide Vial
20 mg lyophilized Cardiogen source compound
Insulin Syringes (U-100)
Precision low-volume measurement and laboratory administration (30-unit or 50-unit recommended)
Bacteriostatic Water
Sterile reconstitution solvent (3.0 mL used per vial)
Alcohol Swabs
Sanitization of vial stoppers and procedural surfaces prior to access
Why researchers study it
Cardiovascular functional modulation
Cardiomyocyte protection and apoptosis reduction
Endothelial and vascular cellular signaling
Bioregulatory aging and longevity mechanisms
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Cardiogen is a synthetic peptide bioregulator consisting of four amino acids with the primary sequence Ala-Glu-Asp-Arg (AEDR). Originating from the Khavinson group's cytogen series, it was engineered to explore targeted cellular regulation within heart tissue. Investigational protocols evaluate its affinity for cardiac cellular pathways and its role in epigenetic modulation without relying on complex protein scaffolds. In preclinical laboratory models, researchers assess Cardiogen's capacity to support structural integrity in cardiomyocytes, preserve normal cellular life cycles, and counter apoptotic pathways triggered by stress. The compound serves primarily as an experimental model for examining organ-specific micro-peptides and their interaction with cellular repair systems in aging or compromised tissue. Cardiogen remains classified as an investigational research chemical strictly intended for in vitro and animal laboratory evaluations. It has not received regulatory approval from international health agencies for therapeutic administration or diagnostic purposes in humans.
References
- 1.Khavinson VK, Peptides and Ageing, 2002 — Review of Khavinson short-peptide cytogen bioregulators
- 2.Khavinson VK et al., Bulletin of Experimental Biology and Medicine, 2002 — Proposed mechanism of short peptide gene expression regulation
- 3.Preclinical cardiomyocyte studies, PubMed, 2000s — Preclinical cardiomyocyte survival and apoptosis models
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allMazdutide 5mg
Dual GLP-1 and glucagon receptor agonist evaluated in clinical models for robust metabolic regulation and body weight reduction.
View ProtocolPT-141 10mg
A synthetic melanocortin receptor agonist evaluated in clinical and laboratory models for centrally regulated libido and sexual response.
View ProtocolAra-290 16mg
Ara-290 is an EPO-derived peptide targeting the innate repair receptor for neuroprotection, tissue repair, and neuropathic pain research.
View Protocol